Weik Capital Management Sells 2,850 Shares of Pfizer Inc. (NYSE:PFE)

Weik Capital Management lowered its stake in Pfizer Inc. (NYSE:PFE) by 8.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,780 shares of the biopharmaceutical company’s stock after selling 2,850 shares during the quarter. Weik Capital Management’s holdings in Pfizer were worth $870,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. Norges Bank acquired a new position in shares of Pfizer during the fourth quarter worth $2,328,986,000. Caisse Des Depots ET Consignations acquired a new position in Pfizer in the 4th quarter worth about $8,083,000. IQ EQ FUND MANAGEMENT IRELAND Ltd raised its position in Pfizer by 0.7% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 258,310 shares of the biopharmaceutical company’s stock valued at $6,853,000 after purchasing an additional 1,850 shares during the last quarter. Amica Retiree Medical Trust boosted its stake in shares of Pfizer by 53.5% during the fourth quarter. Amica Retiree Medical Trust now owns 17,141 shares of the biopharmaceutical company’s stock valued at $455,000 after purchasing an additional 5,977 shares in the last quarter. Finally, Delta Asset Management LLC TN grew its holdings in shares of Pfizer by 15.8% during the fourth quarter. Delta Asset Management LLC TN now owns 97,994 shares of the biopharmaceutical company’s stock worth $2,600,000 after purchasing an additional 13,361 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE opened at $25.05 on Friday. The business’s fifty day moving average is $26.09 and its 200 day moving average is $26.97. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $142.08 billion, a P/E ratio of 17.77, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.10 earnings per share. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on PFE. Bank of America reiterated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Citigroup cut their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.